Matthew Henn's Insider Trades & SAST Disclosures
Matthew Henn's most recent trade in Seres Therapeutics Inc was a trade of 7,813 Common Stock done . Disclosure was reported to the exchange on Feb. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew Henn.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 7,813 | 88,396 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 7,813 | 23,437 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.81 per share. | 15 Feb 2025 | 3,953 | 84,443 (0%) | 0% | 0.8 | 3,204 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 2,813 | 22,500 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 2,813 | 80,583 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 650,000 | 650,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,812 | 25,313 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2024 | 2,812 | 78,697 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.54 per share. | 15 Nov 2024 | 927 | 77,770 (0%) | 0% | 0.5 | 501 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2024 | 12,622 | 0 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2024 | 12,622 | 79,869 (0%) | 0% | 0 | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 27 Oct 2024 | 3,984 | 75,885 (0%) | 0% | 0.7 | 2,749 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 2,813 | 28,125 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 2,813 | 68,170 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.84 per share. | 15 Aug 2024 | 923 | 67,247 (0%) | 0% | 0.8 | 775 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,812 | 66,248 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 2,812 | 30,938 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 0.94 per share. | 15 May 2024 | 891 | 65,357 (0%) | 0% | 0.9 | 838 | Common Stock |
| Seres Therapeutics Inc | Henn Matthew | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 287,905 | 287,905 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Henn Matthew | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 187,500 | 187,500 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 31,250 | 31,250 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 11,250 | 67,606 (0%) | 0% | - | Common Stock | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 1.08 per share. | 14 Feb 2024 | 4,170 | 63,436 (0%) | 0% | 1.1 | 4,504 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2023 | 35,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Sep 2022 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 3.15 per share. | 05 Jul 2022 | 47,619 | 47,619 (0%) | 0% | 3.2 | 150,000 | COMMON STOCK |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2021 | 130,000 | 130,000 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 26.56 per share. | 01 Dec 2020 | 55,706 | 36,106 (0%) | 0% | 26.6 | 1,479,551 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 27,562 | 45,938 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.01 per share. | 01 Dec 2020 | 27,562 | 91,812 (0%) | 0% | 6.0 | 165,648 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 27.56 per share. | 01 Dec 2020 | 26,265 | 9,841 (0%) | 0% | 27.6 | 723,863 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 26,250 | 3,750 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.89 per share. | 01 Dec 2020 | 26,250 | 64,250 (0%) | 0% | 9.9 | 259,613 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.71 per share. | 01 Dec 2020 | 26,000 | 38,000 (0%) | 0% | 0.7 | 18,460 | Common Stock |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 26,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Seres Therapeutics Inc | Matthew Henn | See Remarks | Sale of securities on an exchange or to another person at price $ 28.34 per share. | 01 Dec 2020 | 9,841 | 0 (0%) | 0% | 28.3 | 278,894 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges